KalVista Pharmaceuticals, Inc.

DB:4XC1 Stock Report

Market Cap: €479.7m

KalVista Pharmaceuticals Management

Management criteria checks 2/4

KalVista Pharmaceuticals' CEO is Ben Palleiko, appointed in Mar 2024, has a tenure of less than a year. total yearly compensation is $6.77M, comprised of 8.6% salary and 91.4% bonuses, including company stock and options. directly owns 0.62% of the company’s shares, worth €2.96M. The average tenure of the management team and the board of directors is 2.4 years and 3.7 years respectively.

Key information

Ben Palleiko

Chief executive officer

US$6.8m

Total compensation

CEO salary percentage8.6%
CEO tenureless than a year
CEO ownership0.6%
Management average tenure2.4yrs
Board average tenure3.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ben Palleiko's remuneration changed compared to KalVista Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Jul 31 2024n/an/a

-US$142m

Apr 30 2024US$7mUS$580k

-US$127m

Jan 31 2024n/an/a

-US$108m

Oct 31 2023n/an/a

-US$101m

Jul 31 2023n/an/a

-US$95m

Apr 30 2023US$2mUS$515k

-US$93m

Jan 31 2023n/an/a

-US$91m

Oct 31 2022n/an/a

-US$92m

Jul 31 2022n/an/a

-US$89m

Apr 30 2022US$3mUS$490k

-US$82m

Jan 31 2022n/an/a

-US$73m

Oct 31 2021n/an/a

-US$61m

Jul 31 2021n/an/a

-US$52m

Apr 30 2021US$1mUS$435k

-US$46m

Jan 31 2021n/an/a

-US$38m

Oct 31 2020n/an/a

-US$37m

Jul 31 2020n/an/a

-US$33m

Apr 30 2020US$1mUS$435k

-US$29m

Jan 31 2020n/an/a

-US$31m

Oct 31 2019n/an/a

-US$26m

Jul 31 2019n/an/a

-US$23m

Apr 30 2019US$2mUS$366k

-US$21m

Jan 31 2019n/an/a

-US$13m

Oct 31 2018n/an/a

-US$14m

Jul 31 2018n/an/a

-US$16m

Apr 30 2018US$821kUS$340k

-US$16m

Compensation vs Market: Ben's total compensation ($USD6.77M) is above average for companies of similar size in the German market ($USD1.03M).

Compensation vs Earnings: Ben's compensation has increased whilst the company is unprofitable.

CEO

Ben Palleiko (58 yo)

less than a year

Tenure

US$6,772,197

Compensation

Mr. Benjamin L. Palleiko, also known as Ben, has been Director and Chief Executive Officer of KalVista Pharmaceuticals, Inc. from March 07, 2024. He served as President of KalVista Pharmaceuticals, Inc. fr...

Leadership Team

NamePositionTenureCompensationOwnership
Benjamin Palleiko
CEO & Directorless than a yearUS$6.77m0.62%
€ 3.0m
Christopher Yea
Chief Development Officer9yrsUS$1.37m0.21%
€ 998.8k
Paul Audhya
Chief Medical Officer3.5yrsUS$1.83m0.22%
€ 1.0m
Brian Piekos
Chief Financial Officerless than a yearno datano data
Ryan Baker
Head of Investor Relationsno datano datano data
Brian Krex
General Counselno datano datano data
Jarrod Aldom
Vice President of Corporate Communicationsno datano datano data
Rachel Morten
Senior Vice President of Regulatory Affairs & QAno datano datano data
Michael Smith
Senior Vice President of Development5.5yrsno datano data
Nicole Sweeny
Chief Commercial Officer1.3yrsno datano data
Stephen Donnelly
Director of Finance and Company Secretaryno datano datano data

2.4yrs

Average Tenure

51yo

Average Age

Experienced Management: 4XC1's management team is considered experienced (2.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Benjamin Palleiko
CEO & Directorless than a yearUS$6.77m0.62%
€ 3.0m
Edward Unkart
Independent Director9.9yrsUS$136.60k0%
€ 0
Brian J. Pereira
Independent Chairman5.8yrsUS$161.60k0%
€ 0
Nancy Stuart
Independent Director3.7yrsUS$136.60k0%
€ 0
William Fairey
Independent Directorless than a yearUS$143.78kno data
Tomas Kiselak
Board Observer9.3yrsno datano data
Patrick Treanor
Independent Director2.5yrsUS$124.10k0%
€ 0

3.7yrs

Average Tenure

60yo

Average Age

Experienced Board: 4XC1's board of directors are considered experienced (3.7 years average tenure).